Canadian patients are now paying a fraction of the price for generic semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, while their American counterparts continue to face exorbitant costs. This stark transatlantic divide has prompted experts to label the US drug pricing system a catastrophic market failure, one that prioritises shareholder returns over public health.
The Canadian rollout began in early 2024, with generic versions entering the market at roughly 15% of the US list price. A month’s supply now costs around C$150, compared to US$935 in the United States. The savings are dramatic and immediate, yet they expose a deeper dysfunction. Why can Canada, a market one-tenth the size, achieve such pricing efficiency?
The answer lies in Canada’s Patented Medicine Prices Review Board, a federal body that caps excessive pricing. The US relies instead on a labyrinth of middlemen, pharmacy benefit managers, and patent thickets. This is not a free market; it is a rigged game where monopoly rents accrue to drugmakers. Generic competition in Canada arrived within weeks of the patent expiry, thanks to streamlined regulatory approvals. In the US, manufacturers often employ “pay-for-delay” tactics, stalling generics for years.
The fiscal implications are severe. Medicare Part D alone spent US$6.2 billion on Ozempic in 2023. With generics available north of the border, that figure is a monument to wasted taxpayer money. The Congressional Budget Office estimates that allowing Medicare to negotiate prices, as Canada does, would save US$500 billion over a decade. Yet the pharmaceutical lobby fights tooth and nail to preserve the status quo.
British readers will note a familiar pattern. The NHS negotiates bulk discounts that yield prices far below US levels. The UK’s National Institute for Health and Care Excellence (NICE) assesses cost-effectiveness, a concept that remains anathema across the Atlantic. The result is that the US, the world’s richest healthcare market, pays the highest drug prices on earth.
From a market efficiency standpoint, the US system is a grotesque anomaly. Competitive dynamics should drive prices down over time, but instead they spiral upward. The problem is structural: patent protections create temporary monopolies, and the lack of price controls allows companies to extract maximum value. The Canadian example proves that competition works when the regulatory framework allows it.
The capital flight implications are equally troubling. Foreign investors pour money into US biotech firms specifically because of their pricing power. A crackdown on drug prices would dent valuations and potentially slow innovation. But the current system already stifles innovation in a different way: it directs research toward minor variations of lucrative drugs rather than genuine breakthroughs.
For the City of London, the lesson is clear. The UK’s regulatory balance, while imperfect, avoids the worst excesses. But the US disconnect should serve as a warning. When a single drug can cost the healthcare system billions, it becomes a fiscal risk that eventually hits bond yields and inflation expectations. The Federal Reserve cannot ignore such pricing distortions forever.
In conclusion, Canada’s generic Ozempic success is not just a consumer win; it is a damning indictment of US drug pricing policy. The market is failing, and the price is paid by patients and taxpayers alike. Until the US embraces sensible regulation, the anomaly will persist as a stark reminder of what political capture looks like in practice.
